mdm-2 gene amplification in 3T3-L1 preadipocytes

Differentiation

Volumn 64, Issue 4, 1999, Pages 205-212

  Berberich, Steven J ^a   Litteral, Vaughn ^a   Mayo, Lindsey D ^a,b   Tabesh, Dara ^a   Morris, David ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN MDM2;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN 3T3; DEVELOPMENTAL GENETICS; FIBROBLAST; GENE AMPLIFICATION; MOUSE; MUSCLE DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROADIPOCYTE; PROMOTER REGION; SOUTHERN BLOTTING;

ANIMALIA; MURINAE;

EID: 0032945098     PISSN: 03014681     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-0436.1999.6440205.x     Document Type: Article

References (42)

1. 1. Barak Y, Oren M (1992) Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest. EMBO J 11:2115-2121
2. 2. Barak Y, Gottlieb E, Junve-Gershon T, Oren M (1994) Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev 8:1739-1749
3. 3. Barak Y, Juven T, Haffner R, Oren M (1993) mdm2 expression is induced by wild type p53 activity. EMBO 12:461-468
4. 4. Berberich S, Hyde DN, Espenshade P, Cole M (1992) max encodes a sequence-specific DNA-binding protein and is not regulated by serum growth factors. Oncogene 7:775-779
5. 5. Berberich SJ, Cole MD (1994) The mdm-2 oncogene is translocated and overexpressed in a murine plasmacytoma cell line expressing wild-type p53. Oncogene 9:1469-1472
6. 6. Blagosklonny MV (1997) Loss of function and p53 protein stabilization. Oncogene 15:1889-1893
7. 7. Cahilly-Snyder L, Yang-Feng T, Francke U, George DL (1987) Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet 13:235-244
8. 8. Constance CM, Morgan JIt, Umek RM (1996) C/EBPalpha regulation of the growth-arrest-associated gene grade45. Mol Cell Biol 16:3878-3883
9. 9. El-Diery WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein V (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-835
10. 10. Fakharzadeh SS, Trusko SP, George DL (1991) Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 10:1565-1569
11. 11. Fakharzadeh SS, Rosenblum-Vos L, Murphy M, Hoffman EK, George DL (1993) Structure and organization of amplified DNA on double minutes containing the mdm2 oncogene. Genomics 15:283-290
12. 12. Fiddler TA, Smith L, Tapscott SJ, Thayer MJ (1996) Amplification of MDM2 inhibits MyoD-mediated myogenesis. Mol Cell Biol 16:5048-5057
13. 13. Finlay CA (1993) The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13:301-306
14. 14. Green H, Kehinde O (1974) Sublines of mouse 3T3 cells that accumulate lipid. Cell 1:113-116
15. 15. Green H, Meuth M (1974) An established pre-adipose cell line and its differentiation in culture. Cell 3:127-133
16. 16. Haupt Y, Maya R, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296
17. 17. Mermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B (1997) 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell1:3-11
18. 18. Hupp TR, Meek DW, Midgley CA, Lane DP (1992) Regulation of the specific DNA binding function of p53. Cell 71:875-886
19. 19. Hupp TR, Spark A, Lane DP (1995) Small peptide activate the latent sequence-specific DNA binding function of p53. Cell 83:237-245
20. 20. Jiang H, Lin J, Su Z, Collart FR, Huberman E, Fisher PB (1994) Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21 WAF1/C1P1, expression in the absence of p53. Oncogene 9:3397-3406
21. 21. Juven T, Barak Y, Zauberman A, George DL, Oren M (1993) Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8: 3411-3416
22. 22. Kubbutat MHG, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387:299
23. 23. Landers JE, Haines DS, Strauss JF, George DL (1994) Enhanced translation: a novel mechanisms of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 9: 2745-2750
24. 24. Landers JE, Cassel SL, George DL (1997) Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res 57:3562
25. 25. Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351:453-456
26. 26. Martin K, Trouche D, Hagemeier C, Sorensen TS, LaThangue NB, Kouzarides T (1995) Stimulation of E2F1/DP1 transcriptional activity by Mdm-2 oncoprotein. Nature 375: 691-694
27. 27. Mayo LD, Berberich SJ (1996) Wild type p53 proteins is unable to activate the mdm-2 gene during F9 cell differentiation. Oncogene 13:2315-2321
28. 28. Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299
29. 29. Momand J, Zambetti GP (1997) Mdm2: "Big Brother" of p53. J Cell Biochem 64:343-352
30. 30. Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245
31. 31. Mosner J, Deppert W (1994) p53 and mdm2 are expressed independently during cellular proliferation. Oncogene 9:3321-3328
32. 32. Oliner JD, Kinzler DW, Meltzer PS, George DL, Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83
33. 33. Olson DC, Marechal V, Momand J, Chen J, Romocki C, Levine AJ (1993) Identification and characterization of multiple Mdm-2 proteins and Mdm-2-p53 protein complexes. Oncogene 8:2353-2360
34. Cip1 in muscle and other terminally differentiating cells. Science 267:1024-1027
35. 35. Perry ME, Piette J, Zawadzki JA, Harvey D, Levine AJ (1993) The mdm-2 gene is induced in response to UV light in a p53-dependent. Proc Natl Acad Sci USA 90:11623-11627
36. 36. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E (1998) DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12:2831-2841
37. 37. Saucedo LJ, Carstens BP, Seavey SE, Albee LD II, Perry ME (1998) Regulation of transcriptional activation of mdm2 gene by p53 in response to UV radiation. Cell Growth Differ 9:119-130
38. 38. Sigalas I, Calvert AH, Anerson JJ, Neal DE, Lunec J (1996) Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 2:912-917
39. 39. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB (1997) DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 11:3471-3481
40. 40. Weinberg WC, Azzoli CG, Chapman K, Levine AJ, Yuspa SH (1995) p53-mediated transcriptional activity increases in differentiating epidermal keratinocytes in association with decreased p53 protein. Oncogene 10:2271-1279
41. 41. Wu X, Bayle JH, Olson D, Levine AJ (1993) The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7:1126-1132
42. 42. Xiao Z-X, Chen J, Levine AJ, Nodjtahedi N, Xing J, Sellers WR, Livingston DM (1995) Interaction between the retinoblastoma protein and the oncoprotein Mdm-2. Nature 375: 694-698